Physician profile
Candace Wulff
NPI 1760903538
$12,407.81
in general payments reported to CMS, 2019-2025
24 companies · $1,696 in 2025
The $1,696 reported for 2025 was more than what 80% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $315 · 2022: $1,920 · 2023: $3,042 · 2024: $5,191 · 2025: $1,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,687 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,686.56 |
| Education | $242.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,802.96 | 2023-2025 | Indigo System, Penumbra System |
| Abbott Laboratories | $1,786.63 | 2023-2025 | Jeti, Jeti Peripheral Catheter, Perclose Prostyle |
| Medtronic, INC. | $1,348.54 | 2022-2025 | Endurant Iis, Valiant Captivia, Abre |
| Kerecis Limited | $1,276.81 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| W. L. Gore & Associates, INC. | $1,163.83 | 2022-2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Excluder Conformable Aaa Endoprosthesis With Active Control, Gore Excluder Aaa Endoprosthesis |
| Cook Medical LLC | $906.71 | 2023-2025 | Zilver Ptx, Zenith, Zilver Vena |
| Endologix LLC | $808.87 | 2022-2023 | Alto Abdominal Stent Graft System, Afx2 Bifurcated Endograft System |
| Silk Road Medical, INC. | $580.74 | 2023-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Bolton Medical INC | $418.06 | 2022-2024 | Treo Abdominal Stent-Graft System |
| Kci USA, INC. | $311.42 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $299.45 | 2025 | Rotarexs 6 F X 135 Cm, Lutonix Drug Coated Balloon, Lifestent Solo Vascular Stent |
| Sanara Medtech INC. | $289.74 | 2024 | Celleraterx |
| Abbvie INC. | $286.59 | 2023-2024 | Natrelle Saline-Filled Breast Implants |
| Musculoskeletal Transplant Foundation INC. | $277.14 | 2019-2020 | |
| Shockwave Medical, INC | $235.69 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $173.12 | 2022 | |
| Cordis US Corp. | $122.51 | 2024 | Angioguard |
| Allergan, INC. | $106.70 | 2022 | |
| Asahi Intecc USA, INC. | $78.98 | 2022-2023 | Asahi Ptca Guide Wire |
| Stryker Corporation | $42.21 | 2025 | Clottriever Bold Catheter |
| Surmodics, INC. | $39.60 | 2023 | Pounce Venous Thrombectomy System |
| Solventum Corporation | $19.07 | 2024 | V.A.C. Veraflo, Prevena, V.A.C. Dermatac |
| Ethicon US, LLC | $16.81 | 2019 | |
| Boston Scientific Corporation | $15.63 | 2025 | Enroute Transcarotid Stent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Wulff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.